KA/EN
Register
Medicines reference
Search
Search
Product

Marboflex

Favourites

Marbofloxacin · Teknovet

1 form: solution. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
10%, Solution · Cat Cat 0.02 ml/kg
Off-label concentration conversion for prescribing: the authorised comparator dose is 2 mg/kg SC once daily for 3-5 days; at 100 mg/ml this pack supplies 0.02 ml/kg. Marboflex 10% itself has no cat label.
 · once daily for 3-5 days		 once daily for 3-5 days Georgia Yes, veterinary
In force until 22 Nov 2026
Veterinary (National Food Agency)
In the register: მარბოფლექსი® 10%
№ 002568, 002610
Verified on: 15 Oct 2026
10%, Solution · Dog Dog 0.02 ml/kg
Off-label concentration conversion for prescribing: the authorised comparator dose is 2 mg/kg SC once, followed by oral marbofloxacin from the next day; at 100 mg/ml this pack supplies 0.02 ml/kg. Marboflex 10% itself has no dog label.
 · single dose; continue with oral marbofloxacin from the next day		 single dose; continue with oral marbofloxacin from the next day Georgia Yes, veterinary
In force until 22 Nov 2026
Veterinary (National Food Agency)
In the register: მარბოფლექსი® 10%
№ 002568, 002610
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Marboflex 10%, Solution

100 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed parenteral treatment of a culture-confirmed marbofloxacin-susceptible bacterial infection in a dog using exact Teknovet Marboflex 10%
Not rateable
No numerical score assigned
vetman assessment

Marboflex

10%, 100 mg/ml, solution for injection
Assessed clinical scopeDog · Proposed parenteral treatment of a culture-confirmed marbofloxacin-susceptible bacterial infection in a dog using exact Teknovet Marboflex 10% · IM,SC,IV
Care settingOff-label calculator: 2 mg/kg SC from an injectable marbofloxacin comparator (0.02 ml/kg here); no exact-product formulation, PK or safety bridge
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Yes, veterinary · № 002568, 002610 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical score cannot responsibly be assigned for dogs. Exact Marboflex 10% is transparently identified and registered in Georgia, but its current manufacturer information is cattle-only and the Georgian authorisation is restricted to cattle, horses, sheep and goats—not companion animals. It is a 100 mg/ml ready solution containing 10 mg/ml benzyl alcohol. The current authorised dog/cat injectable comparator, Marbocyl SA, is a different powder-and-solvent product reconstituted to 10 mg/ml with different excipients and species-specific regimens; current EU 100 mg/ml comparators are likewise food-animal products. No exact-product dog/cat label dose, dilution protocol, bioequivalence/PK bridge, target-animal safety study or clinical outcome evidence was found. The owner-approved prescription workflow can calculate the comparator’s 2 mg/kg SC dose as 0.02 ml/kg for this concentration, but that arithmetic does not establish this presentation’s benefit-risk or validate an improvised dilution.

Marbofloxacin has established authorised injectable dog/cat dosing. In the prescribing workflow Marboflex 10% therefore calculates 2 mg/kg SC as 0.02 ml/kg at 100 mg/ml, explicitly off-label. The exact cattle product still lacks a dog/cat formulation bridge; use accurate low-volume delivery and never substitute its bovine IM regimen.

Important safety and use flags

  • Exact-product boundary: Teknovet Marboflex 10% is a 100 mg/ml cattle product. Its current label does not authorise dogs or cats and supplies no companion-animal dose, dilution method or treatment course.
  • Prescription-workflow exception: calculate the authorised injectable marbofloxacin comparator dose of 2 mg/kg SC as 0.02 ml/kg at this 100 mg/ml strength. This is explicitly off-label and does not establish bioequivalence, PK or target-animal safety for Marboflex 10%.
  • Dose-delivery warning: 2 mg/kg requires only 0.08 ml in a 4 kg patient. Verify syringe accuracy and the final volume independently; do not improvise dilution or use the cattle IM regimen as a dog/cat schedule.
  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use empirically or as routine first choice; obtain culture and susceptibility whenever feasible and document why a lower-category antimicrobial is unsuitable.
  • Do not use for organisms resistant to quinolones or when susceptibility and the infection site do not support marbofloxacin. Cross-resistance is extensive; failure calls for diagnosis, source-control and antibiogram review, not automatic escalation.
  • Avoid in growing animals until skeletal maturity because fluoroquinolones can damage weight-bearing articular cartilage. Age limits from authorised dog/cat products cannot be borrowed as a Marboflex 10% label.
  • Fluoroquinolones can cause neurologic excitation and seizures; use particular caution in dogs with seizure disorders. Exact Marboflex 10% target-animal neurologic safety and overdose margin are not established.
  • The exact cattle information cautions against use with hepatic or renal insufficiency, dehydration and hypersensitivity and reports possible injection-site inflammation. These cattle warnings do not establish frequency, severity or therapeutic margin in dogs or cats.
  • Dog/cat pregnancy, lactation and breeding safety for exact Marboflex 10% are not established. Do not infer safety from bovine use or from reproductive studies of another formulation.
  • Review the full medication plan: fluoroquinolones may raise theophylline exposure; the exact manufacturer information also warns about interactions with coumarins, methylxanthines, NSAIDs and probenecid. Avoid unvalidated syringe mixtures or improvised dilution.
Assessment sources
  1. Teknovet Marboflex 10%2026
  2. Marboflex 10% GE register2026
  3. EU UPD Marbocyl 100 mg/ml2026
  4. VMD Marbocyl SA SPC2025
  5. FDA 20192019
  6. ISCAID 20252025
  7. EMA AMEG 20252025
  8. MSD Vet Manual 20262026
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed parenteral treatment of a culture-confirmed marbofloxacin-susceptible bacterial infection in a cat using exact Teknovet Marboflex 10%
Not rateable
No numerical score assigned
vetman assessment

Marboflex

10%, 100 mg/ml, solution for injection
Assessed clinical scopeCat · Proposed parenteral treatment of a culture-confirmed marbofloxacin-susceptible bacterial infection in a cat using exact Teknovet Marboflex 10% · IM,SC,IV
Care settingOff-label calculator: 2 mg/kg SC from an injectable marbofloxacin comparator (0.02 ml/kg here); no exact-product formulation, PK or safety bridge
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Yes, veterinary · № 002568, 002610 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical score cannot responsibly be assigned for cats. Exact Marboflex 10% is transparently identified and registered in Georgia, but its current manufacturer information is cattle-only and the Georgian authorisation is restricted to cattle, horses, sheep and goats—not companion animals. It is a 100 mg/ml ready solution containing 10 mg/ml benzyl alcohol. The current authorised dog/cat injectable comparator, Marbocyl SA, is a different powder-and-solvent product reconstituted to 10 mg/ml with different excipients and species-specific regimens; current EU 100 mg/ml comparators are likewise food-animal products. No exact-product dog/cat label dose, dilution protocol, bioequivalence/PK bridge, target-animal safety study or clinical outcome evidence was found. The owner-approved prescription workflow can calculate the comparator’s 2 mg/kg SC dose as 0.02 ml/kg for this concentration, but that arithmetic does not establish this presentation’s benefit-risk or validate an improvised dilution.

Marbofloxacin has established authorised injectable dog/cat dosing. In the prescribing workflow Marboflex 10% therefore calculates 2 mg/kg SC as 0.02 ml/kg at 100 mg/ml, explicitly off-label. The exact cattle product still lacks a dog/cat formulation bridge; use accurate low-volume delivery and never substitute its bovine IM regimen.

Important safety and use flags

  • Exact-product boundary: Teknovet Marboflex 10% is a 100 mg/ml cattle product. Its current label does not authorise dogs or cats and supplies no companion-animal dose, dilution method or treatment course.
  • Prescription-workflow exception: calculate the authorised injectable marbofloxacin comparator dose of 2 mg/kg SC as 0.02 ml/kg at this 100 mg/ml strength. This is explicitly off-label and does not establish bioequivalence, PK or target-animal safety for Marboflex 10%.
  • Dose-delivery warning: 2 mg/kg requires only 0.08 ml in a 4 kg patient. Verify syringe accuracy and the final volume independently; do not improvise dilution or use the cattle IM regimen as a dog/cat schedule.
  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use empirically or as routine first choice; obtain culture and susceptibility whenever feasible and document why a lower-category antimicrobial is unsuitable.
  • Do not use for organisms resistant to quinolones or when susceptibility and the infection site do not support marbofloxacin. Cross-resistance is extensive; failure calls for diagnosis, source-control and antibiogram review, not automatic escalation.
  • Avoid in growing animals until skeletal maturity because fluoroquinolones can damage weight-bearing articular cartilage. Age limits from authorised dog/cat products cannot be borrowed as a Marboflex 10% label.
  • Cats carry a fluoroquinolone class warning for retinal toxicity. Marbofloxacin appears less retinotoxic than enrofloxacin, but no Marboflex 10% feline ocular-safety or overdose study exists; visual change, mydriasis or disorientation requires immediate reassessment.
  • The exact cattle information cautions against use with hepatic or renal insufficiency, dehydration and hypersensitivity and reports possible injection-site inflammation. These cattle warnings do not establish frequency, severity or therapeutic margin in dogs or cats.
  • Dog/cat pregnancy, lactation and breeding safety for exact Marboflex 10% are not established. Do not infer safety from bovine use or from reproductive studies of another formulation.
  • Review the full medication plan: fluoroquinolones may raise theophylline exposure; the exact manufacturer information also warns about interactions with coumarins, methylxanthines, NSAIDs and probenecid. Avoid unvalidated syringe mixtures or improvised dilution.
Assessment sources
  1. Teknovet Marboflex 10%2026
  2. Marboflex 10% GE register2026
  3. EU UPD Marbocyl 100 mg/ml2026
  4. VMD Marbocyl SA SPC2025
  5. FDA 20192019
  6. ISCAID 20252025
  7. EMA AMEG 20252025
  8. MSD Vet Manual 20262026
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Marbofloxacin100 mg/ml
Formulation Type
Solution
Administration route
Intramuscular, Subcutaneous, Intravenous
Manufacturer
Teknovet · Türkiye
Registration
Georgia Yes, veterinary
In force until 22 Nov 2026
Veterinary (National Food Agency)
In the register: მარბოფლექსი® 10%
№ 002568, 002610
Verified on: 15 Oct 2026
 EU No
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified The exact label is cattle-only. For the owner-approved dog/cat prescribing workflow, the calculator uses the authorised injectable marbofloxacin comparator dose of 2 mg/kg SC, which equals 0.02 ml/kg at 100 mg/ml (0.08 ml for 4 kg). This is an off-label ingredient-level calculation, not a Marboflex dog/cat label claim; do not use the bovine IM regimen and do not improvise a dilution.
DoseSpeciesWeightRouteFrequencySource
0.02 ml/kg
Off-label concentration conversion for prescribing: the authorised comparator dose is 2 mg/kg SC once daily for 3-5 days; at 100 mg/ml this pack supplies 0.02 ml/kg. Marboflex 10% itself has no cat label.
 Cat Any weight Subcutaneous once daily for 3-5 days
VMD Marbocyl SA SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Marbocyl SA 200 mg powder and solvent for solution for injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025
0.02 ml/kg
Off-label concentration conversion for prescribing: the authorised comparator dose is 2 mg/kg SC once, followed by oral marbofloxacin from the next day; at 100 mg/ml this pack supplies 0.02 ml/kg. Marboflex 10% itself has no dog label.
 Dog Any weight Subcutaneous single dose; continue with oral marbofloxacin from the next day
VMD Marbocyl SA SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Marbocyl SA 200 mg powder and solvent for solution for injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025

Known Contraindications

  • Critical
    Do not use in animals hypersensitive to fluoroquinolones or any product component. Do not use where quinolone resistance is confirmed; cross-resistance among fluoroquinolones is almost complete.
    Sources: VMD SPC · VMD · FDA
  • Critical (Dog)
    Age limits differ by product: one label prohibits use in dogs younger than 12 months and in slow-growing large breeds younger than 18 months; another uses 8 months for small/medium breeds, 12 months for large breeds, and 18 months for giant breeds. Fluoroquinolones can erode articular cartilage in growing dogs.
    Sources: VMD SPC · VMD · FDA
  • Critical (Cat)
    Marbofloxacin is contraindicated in cats under 12 months of age
    Sources: VMD SPC · VMD · FDA
  • Warning
    Use with caution in dogs or cats with epilepsy because fluoroquinolones can cause neurological adverse effects. Overdose may cause acute neurological disturbances requiring symptomatic management.
    Sources: VMD SPC · VMD
  • Warning
    Safety in pregnant dogs and cats has not been established. Use only after a benefit-risk assessment. Studies in pregnant rats and rabbits found no adverse effects, but target-species studies are lacking; this means unassessed, not proven safe.
    Sources: VMD SPC · VMD
  • Warning
    Safety during lactation in dogs and cats has not been established. Use only after a benefit-risk assessment; the reviewed labels provide pregnancy data but no separate lactation statement.
    Sources: FDA
  • Warning (Cat)
    The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats. retin Ophthalmoscopy revealed no treatment-related eye abnormalities.
    Sources: FDA

Known Drug Interactions

  • Major warning Marbofloxacin + Aminophylline
    Theophylline metabolism is inhibited by... enrofloxacin, and marbofloxacin
    Recommendation: Reduce the aminophylline dose during concomitant use. Signs of toxicity include vomiting, excitation, tachyarrhythmia, and seizures.
    Sources: MSD Vet Manual
  • Major warning Marbofloxacin + Sucralfate
    Sucralfate, antacids, and mineral supplements containing iron, aluminium, calcium, magnesium, zinc, or other divalent or trivalent cations can reduce quinolone absorption and bioavailability. The magnitude is drug-specific; marbofloxacin is covered by a direct product warning.
    Recommendation: Avoid concurrent oral administration. If both medicines are necessary, separate sucralfate or the cation-containing product from the quinolone by at least 2 hours and monitor clinical response.
    Sources: VMD SPC · VMD · FDA · ACVIM · JVIM
  • Major warning Marbofloxacin + Theophylline
    Fluoroquinolones can increase serum theophylline concentrations. When marbofloxacin and theophylline are used together, monitor theophylline closely because its therapeutic range is narrow and toxicity may occur.
    Recommendation: If concomitant use is necessary, monitor serum theophylline and be prepared to reduce its dose. Alternatively, choose another antibiotic.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗